The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes
Open accessAbstract
BACKGROUND: Cardiovascular morbidity is a major burden in patients with type 2 diabetes. In the Steno-2 Study, we compared the effect of a targeted, intensified, multifactorial intervention with that of conventional treatment on modifiable risk factors for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. METHODS: The primary end point of this open, parallel trial was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, revascularization, and amputation. Eighty patients were randomly assigned to receive conventional treatment in accordance with national guidelines and 80 to receive intensive treatment, with a stepwise implementation of behavior modification and pharmacologic therapy that targeted hyperglycemia, hypertension, dyslipidemia, and microalbuminuria, along with secondary prevention of cardiovascular disease with aspirin. RESULTS: The mean age of the patients was 55.1 years, and the mean follow-up was 7.8 years. The decline in glycosylated hemoglobin values, systolic and diastolic blood pressure, serum cholesterol and triglyceride levels measured after an overnight fast, and urinary albumin excretion rate were all significantly greater in the intensive-therapy group than in the conventional-therapy group. Patients receiving intensive therapy also had a significantly lower risk of cardiovascular disease (hazard ratio, 0.47; 95 percent confidence interval, 0.24 to 0.73), nephropathy (hazard ratio, 0.39; 95 percent confidence interval, 0.17 to 0.87), retinopathy (hazard ratio, 0.42; 95 percent confidence interval, 0.21 to 0.86), and autonomic neuropathy (hazard ratio, 0.37; 95 percent confidence interval, 0.18 to 0.79). CONCLUSIONS: A target-driven, long-term, intensified intervention aimed at multiple risk factors in patients with type 2 diabetes and microalbuminuria reduces the risk of cardiovascular and microvascular events by about 50 percent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although HRV testing is largely confined to the research setting, the CV reflex tests that assess changes in HRV during standardized clinical challenges such as deep breathing, Valsalva maneuver and supine-to-standing position remain the gold standard tests and are available for clinical care as well.547,614,626”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [626]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to traditional risk factors, hyperglycemia, hyperinsulinemia, and oxidative stress contribute to endothelial damage, leading to poor arterial function and greater susceptibility to atherogenesis ( 45 , 82 , 289 ).”
From Exercise and Type 2 Diabetes (2010) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, studies in people with T2D and early CKD demonstrated the long-term bene fi t of multifactorial intervention on the development of microvascular and macrovascular complications and mortality.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Results from several randomized controlled trials revealed that more intensive treatment of risk factors in people with increased levels of natriuretic peptides reduces the risk for symptomatic heart failure, heart failure hospitalization, and newly diagnosed left ventricular dysfunction (222,227,228).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [227]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Results from several randomized controlled trials revealed that more intensive treatment of risk factors in people with increased levels of natriuretic peptides reduces the risk for symptomatic heart failure, heart failure hospitalization, and newly diagnosed left ventricular dysfunction (211,216,217).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [216]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For people who already have diabetes, lifestyle modification and pharmacological treatment, as well as blood pressure and cholesterol control, can delay progression to complications and reduce mortality, or even help with remission, especially if started early.1,2,58–62”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [58]
Experimental — accuracy not yet measuredIn the citing paper
“The benefit of the intensive multifactorial intervention was demonstrated by a significant reduction in the incidence of microvascular complications after 4 years, and a significant 53% risk reduction in macrovascular complications after 8 years.455”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [455]
In the citing paper
“Angiotensin-converting enzyme inhibitors812), angiotensin Ⅱ receptor blockers813), and calcium channel antagonists814) have been reported to be effective for preventing cardiovascular events in patients with DM.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [813]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 4,803
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Research works printed but not linked: 2
- 10.1001/jama.241.19.2035 · DOI · Paper page
- 10.1001/archinte.151.6.1141 · DOI
Cited by
Sorted by citations
Items 601–700 of 1,025
Achieving brain clearance and preventing neurodegenerative diseases—A glymphatic perspective
Kylkilahti, T. M., Berends, E., Ramos, M., Shanbhag, N. C., Töger, J., Bloch, K. M., & Lundgaard, I. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20982388 · Cited by 91
Can diabetes medication be reduced in elderly patients?
Sjöblom, P., AndersTengblad, Löfgren, U.-B., Lannering, C., Anderberg, N., Rosenqvist, U., Mölstad, S., & Östgren, C. J. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.08.014 · Cited by 89
KONES, R. J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37119 · Cited by 91
Pedersen, O. B., & Gæde, P. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00213-0 · Cited by 89
Self-citationZhu, Q., Tong, Y., Wu, T., Li, J., & Tong, N. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.03.020 · Cited by 89
Tahrani, A. A., Dubb, K., Raymond, N. T., Begum, S., Altaf, Q. A., Sadiqi, H., Piya, M. K., & Stevens, M. J. (2014) · Diabetologia · doi:10.1007/s00125-014-3211-2 · Cited by 89
Protection of pancreatic beta-cells: Is it feasible?
Bonora, E. (2007) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.05.004 · Cited by 90
Nosadini, R., Velussi, M., Brocco, E., Abaterusso, C., Carraro, A., Piarulli, F., Morgia, G., Satta, A. E., Faedda, R., Abhyankar, A., et al. (2006) · Diabetes · doi:10.2337/diabetes.55.01.06.db05-0881 · Cited by 90
Hayden, M. R., & Tyagi, S. C. (2003) · Cardiovascular Diabetology · doi:10.1186/1475-2840-2-2 · Cited by 89
Drug/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets
Saxena, A., Balaramnavar, V. M., Hohlfeld, T., & Saxena, A. K. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.032 · Cited by 88
Diabetes guidelines: easier to preach than to practise?
Bryant, W., Greenfield, J. R., Chisholm, D. J., & Campbell, L. V. (2006) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00583.x · Cited by 88
Glycemic Control in Diabetic CKD Patients: Where Do We Stand?
Kovesdy, C. P., Sharma, K., & Kalantar‐Zadeh, K. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.04.011 · Cited by 88
Type 2 diabetes does not increase risk of depression
Brown, L. C. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.051429 · Cited by 90
Impaired Glycemia and Diabetic Polyneuropathy
Dyck, P. J. B., Clark, V. M., Overland, C. J., Davies, J. L., Pach, J. M., Dyck, P. J. B., Klein, C. J., Rizza, R. A., Melton, L. J., Carter, R. E., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1421 · Cited by 88
Voulgari, C., Psallas, M., Kokkinos, A. D., Argiana, V., Katsilambros, N. L., & Tentolouris, N. (2010) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2010.06.001 · Cited by 91
Smith, A. G., & Singleton, J. R. (2012) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000411568.34085.3e · Cited by 90
Takayama, Y., & Aoki, R. (2012) · Biochemistry and Cell Biology · doi:10.1139/o11-054 · Cited by 87
Zhao, Y., Crimmins, E. M., Hu, P., Shen, Y., Smith, J. P., Strauss, J. A., Wang, Y., & Zhang, Y. (2016) · International Journal of Public Health · doi:10.1007/s00038-015-0780-x · Cited by 87
Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases
Guerra, J. V. D. S., Dias, M. M. G., Brilhante, A. J. V. C., Terra, M. F., García‐Arévalo, M., & Figueira, A. C. M. (2021) · Nutrients · doi:10.3390/nu13082830 · Cited by 92
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 101
Newlin, K., Dyess, S. M., Allard, E., Chase, S. K., & Melkus, G. D. (2011) · Journal of Religion and Health · doi:10.1007/s10943-011-9481-9 · Cited by 95
Yadav, D., Mahajan, S. K., Subramani, S. K., Bisen, P. S., Chung, C. H., & Prasad, G. B. K. S. (2013) · Global Journal of Health Science · doi:10.5539/gjhs.v5n6p142 · Cited by 87
Briguori, C., Condorelli, G., Airoldi, F., Focaccio, A., D’Andrea, D., Cannavale, M., Abarghouei, A. A., Giordano, S. A., Vivo, F. D., Ricciardelli, B., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.10.031 · Cited by 87
Anselmino, M., Malmberg, K., Öhrvik, J., Rydén, L., & and on behalf of the Euro Heart Survey Investigators (2008) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3282f335d0 · Cited by 87
Oellgaard, J., Gæde, P., Rossing, P., Rørth, R., Køber, L., Parving, H.-H., & Pedersen, O. (2018) · Diabetologia · doi:10.1007/s00125-018-4642-y · Cited by 86
Self-citationCardiac Autonomic Neuropathy: Why Should Cardiologists Care about That?
Bissinger, A. (2017) · Journal of Diabetes Research · doi:10.1155/2017/5374176 · Cited by 86
The trials and tribulations of determining HbA1c targets for diabetes mellitus
Klein, K. R., & Buse, J. B. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00425-6 · Cited by 91
Banerjee, D., Winocour, P. H., Chowdhury, T. A., De, P., Wahba, M. M., Montero, R., Fogarty, D. G., Frankel, A., Karalliedde, J. J., Mark, P. B., et al. (2022) · BMC Nephrology · doi:10.1186/s12882-021-02587-5 · Cited by 92
Braga, M. F. B., Casanova, A., Teoh, H., Dawson, K. G., Gerstein, H. C., FITCHETT, D. H., Harris, S. B., Honos, G. N., McFarlane, P. A., Steele, A., et al. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)70393-7 · Cited by 86
High prevalence of diabetes and impaired fasting glucose in urban Latin America: the CARMELA Study
Escobedo, J., Buitrón, L. V., Velasco, M. F., Ramírez, J. C., Hernandez, R. C. D., Macchia, A., Pellegrini, F., Schargrodsky, H., Boissonnet, C. P., Champagne, B. M., et al. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02795.x · Cited by 86
Treatment of metabolic syndrome
Wagh, A., & Stone, N. J. (2004) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2.2.213 · Cited by 87
Microalbuminuria: A parameter that has changed diabetes care
Parving, H., Persson, F., & Rossing, P. R. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.10.014 · Cited by 87
Self-citationPi-Sunyer, X. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2056 · Cited by 88
Kidney Disease and Cardiovascular Risk
Tonelli, M. A., & Pfeffer, M. A. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.58.071105.111123 · Cited by 86
Lipotoxicity in Diabetic Nephropathy
Murea, M., Freedman, B. I., Parks, J. S., Antinozzi, P. A., Elbein, S. C., & Ma, L. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08160910 · Cited by 89
Roberts, M. A., Hare, D. L., Ratnaike, S., & Ierino, F. L. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.06.005 · Cited by 86
Diabetes and obesity: therapeutic targeting and risk reduction – a complex interplay
Niswender, K. D. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01175.x · Cited by 89
Janssen, P. G. H., Gorter, K. J., Stolk, R. P., & Rutten, G. E. H. M. (2008) · British Journal of General Practice · doi:10.3399/bjgp09x394851 · Cited by 85
Undertreatment of cardiovascular risk factors among persons with diabetes in the United States
Malik, S., López, V. A. Q., Chen, R. K., Wu, W., & Wong, N. D. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.10.016 · Cited by 85
Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus
Tandon, N., Ali, M. K., & Narayan, K. M. V. (2012) · American Journal of Cardiovascular Drugs · doi:10.2165/11594650-000000000-00000 · Cited by 88
Palmer, A. J., Valentine, W. J., Chen, R., Mehin, N., Gabriel, S., Bregman, B., & Rodby, R. A. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn082 · Cited by 86
Diabetic neuropathy: new strategies for treatment
Várkonyi, T. T., & Kempler, P. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00741.x · Cited by 86
Berikai, P., Meyer, P., Kazlauskaite, R., Savoy, B., Kozik, K., & Fogelfeld, L. A. (2007) · Diabetes Care · doi:10.2337/dc06-2026 · Cited by 85
Hansen, M., Sonne, D. P., Mikkelsen, S. U., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.01.011 · Cited by 86
Prevention of the complications of diabetes.
Vinik, A. I., & Vinik, E. J. (2003) · PubMed · Cited by 85
Mann, J. F. E., Gerstein, H. C., Yi, Q., Franke, J., Lonn, E., Hoogwerf, B. J., Rashkow, A. M., & Yusuf, S. (2003) · American Journal of Kidney Diseases · doi:10.1016/j.ajkd.2003.07.015 · Cited by 85
Effectiveness of Pharmacist‐Administered Diabetes Mellitus Education and Management Services
Ragucci, K. R., Fermo, J. D., Wessell, A. M., & Chumney, E. C. G. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.12.1809 · Cited by 84
The Early Treatment of Type 2 Diabetes
Pratley, R. E. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.06.007 · Cited by 91
Modulation of Adipose Tissue Development by Pharmacological Inhibition of PAI-1
Crandall, D. L., Quinet, E. M., Ayachi, S. E., Hreha, A. L., Leik, C. E., Savio, D. A., Juhan-Vague, I., & Alessi, M. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000235605.51400.9d · Cited by 84
Huelsmann, M., Neuhold, S., Strunk, G., Moertl, D., Berger, R., Prager, R., Abrahamian, H., Riedl, M., Pacher, R., Luger, A., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn334 · Cited by 84
Aguíar, C., Alegría, E., Bonadonna, R. C., Catapano, A. L., Cosentino, F., Elisaf, M., Farnier, M., Ferrières, J., Filardi, P. P., Hâncu, N., et al. (2015) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(15)30001-5 · Cited by 84
Kainz, A., Hronský, M., Stel, V. S., Jager, K. J., Geroldinger, A., Dunkler, D., Heinze, G., Tripepi, G. L., & Oberbauer, R. W. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv073 · Cited by 84
Diabetes and Peripheral Vascular Disease
Huysman, F., & Mathieu, C. (2009) · Acta chirurgica Belgica · doi:10.1080/00015458.2009.11680493 · Cited by 84
Blood Pressure Control in Hypertensive Patients in the "Hiperdia Program": A Territory-Based Study
de Souza, C. S., Stein, A. T., Bastos, G. A. N., & Pellanda, L. C. (2014) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20140081 · Cited by 84
Neuropathy: The Crystal Ball for Cardiovascular Disease?
Vinik, A. I., Maser, R. E., & Ziegler, D. (2010) · Diabetes Care · doi:10.2337/dc10-0745 · Cited by 84
Mechanisms, Significance and Treatment of Vascular Dysfunction in Type 2 Diabetes Mellitus
Woodman, R. J., Chew, G. T., & Watts, G. F. (2005) · Drugs · doi:10.2165/00003495-200565010-00003 · Cited by 83
Long-term outcomes from a multiple-risk-factor diabetes trial for Latinas: ¡Viva Bien!
Toobert, D. J., Strycker, L. A., King, D. K., Barrera, M., Osuna, D., & Glasgow, R. E. (2011) · Translational Behavioral Medicine · doi:10.1007/s13142-010-0011-1 · Cited by 85
Central Adiposity Determines Prevalence Differences of the Metabolic Syndrome
Lorenzo, C., Serrano‐Ríos, M., Martínez‐Larrad, M. T., Gabriel, R., Williams, K., Gómez-Gerique, J. A., Stern, M. P., & Haffner, S. M. (2003) · Obesity Research · doi:10.1038/oby.2003.198 · Cited by 83
Blood pressure control for diabetic retinopathy
Diana, V., Han, G., Abariga, S. A., Sleilati, G. G., Vedula, S. S., & Hawkins, B. S. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006127.pub3 · Cited by 85
on behalf of the Low-Protein Diet Study Group, Koya, D., Haneda, M., Inomata, S., Suzuki, Y., Suzuki, D., Makino, H., Shikata, K., Murakami, Y., Tomino, Y., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1467-8 · Cited by 83
Bhalla, V., Zhao, B., Azar, K. M. J., Wang, E. J., CHOI, S. E., Wong, E. C., Fortmann, S. P., & Palaniappan, L. P. (2012) · Diabetes Care · doi:10.2337/dc12-0951 · Cited by 83
Albuminuria and Vascular Damage — The Vicious Twins
Ritz, E. (2003) · New England Journal of Medicine · doi:10.1056/nejme030066 · Cited by 82
Adding Value to Evidence-Based Clinical Guidelines
O’Connor, P. J. (2005) · JAMA · doi:10.1001/jama.294.6.741 · Cited by 82
Sex Differences in Age-Associated Type 2 Diabetes in Rats—Role of Estrogens and Oxidative Stress
Díaz, A., López-Grueso, R., Gambini, J., Monleón, D., Mas‐Bargues, C., Abdelaziz, K. M., Viña, J., & Borrás, C. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/6734836 · Cited by 81
Genomics and Transcriptomics: The Powerful Technologies in Precision Medicine
Khodadadian, A., Darzi, S., Haghi‐Daredeh, S., Eshaghi, F. S., Babakhanzadeh, E., Mirabutalebi, S. H., & Nazari, M. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s249970 · Cited by 83
GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES
Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M. J., Cosentino, F., Jönsson, B., Laakso, M., Malmberg, K., et al. (2007) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2007-3-4-71-99 · Cited by 81
Echouffo-Tcheugui, J. B., Simmons, R. K., Williams, K. M., Barling, R. S., Prevost, A. T., Kinmonth, A. L., Wareham, N. J., & Griffin, S. J. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-136 · Cited by 81
Reducing Cardiovascular Complications of Type 2 Diabetes by Targeting Multiple Risk Factors
Reasner, C. A. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31817ffe5a · Cited by 82
Screening for Type 2 Diabetes and Dysglycemia
Echouffo-Tcheugui, J. B., Ali, M. K., Griffin, S. J., & Narayan, K. M. V. (2011) · Epidemiologic Reviews · doi:10.1093/epirev/mxq020 · Cited by 87
Okada, T., Nakao, T., Matsumoto, H., Shino, T., Nagaoka, Y., Tomaru, R., & Wada, T. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.6355 · Cited by 80
Nieuwkerk, P. T., Nierman, M. C., Vissers, M. N., Locadia, M., Greggers-Peusch, P., Knape, L. P. M., Kastelein, J. J. P., Sprangers, M. A. G., de Haes, J. C. J. M., & Stroes, E. S. G. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.04.045 · Cited by 80
Sjølie, A. K., Klein, R., Porta, M., Orchard, T. J., Fuller, J., Parving, H.-H., Bilous, R., Aldington, S. J., & Chaturvedi, N. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03210.x · Cited by 81
Self-citationAndrésdóttir, G., Jensen, M. L., Carstensen, B., Parving, H., Rossing, K., Hansen, T. W., & Rossing, P. R. (2014) · Diabetes Care · doi:10.2337/dc13-2036 · Cited by 83
Self-citationUpdate on the management of diabetic polyneuropathies
Stevens, M. J., & Shakher, J. (2011) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s11324 · Cited by 82
Diabetes & coronary heart disease: Current perspectives
Ali, M. K., Narayan, K. M. V., & Tandon, N. (2010) · The Indian Journal of Medical Research · doi:10.4103/ijmr.2010_132_05_584 · Cited by 82
Guidelines on the management of stable angina pectoris
Skalidis, E. I., & Vardas, P. E. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl257 · Cited by 80
Timmons, J. A., Norrbom, J., Schéele, C., Thonberg, H., Wahlestedt, C., & Tesch, P. (2006) · Genomics · doi:10.1016/j.ygeno.2005.09.007 · Cited by 79
Spectrum of Diabetic Neuropathy: New Insights in Diagnosis and Treatment
Dillon, B. R., Ang, L. P., & Pop‐Busui, R. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-033114 · Cited by 85
Guías de práctica clínica para el tratamiento de la hipertensión arterial 2007
(ESH), G. D. T. P. E. T. D. L. H. A. D. L. S. E. D. H., & de Cardiología, D. L. S. E. (2007) · Revista Española de Cardiología · doi:10.1157/13109650 · Cited by 79
Microalbuminuria and risk factors in type 1 and type 2 diabetic patients
Cederholm, J., Eliasson, B., Nilsson, P.-E., Weiss, L. G., & Guðbjörnsdóttir, S. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.07.021 · Cited by 79
Satirapoj, B. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_11 · Cited by 79
Recomendaciones preventivas cardiovasculares
Galán, Á. M. M., Cuixart, C. B., Álvarez, F. V., Pérez, J. N., Lobos-Bejarano, J. M., Sánchez-Pinilla, R. O., Rioboó, E. M., Banegas, J. R. B., Orozco‐Beltrán, D., & Gil-Guillén, V. F. (2012) · Atención Primaria · doi:10.1016/s0212-6567(12)70010-0 · Cited by 78
Ciemins, E. L., Coon, P. J., Peck, R., Holloway, B., & Min, S. (2011) · Telemedicine Journal and e-Health · doi:10.1089/tmj.2011.0028 · Cited by 79
Battisti, W. P., Palmisano, J. J., & Keane, W. F. (2003) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2003.181 · Cited by 78
Cardiovascular disease in chronic kidney disease from a cardiologistʼs perspective
McCullough, P. A. (2004) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200411000-00003 · Cited by 78
The Impact of Prevention on Reducing the Burden of Cardiovascular Disease
Kahn, R., Robertson, R. M., Smith, R. A., & Eddy, D. M. (2008) · Diabetes Care · doi:10.2337/dc08-9022 · Cited by 80
ß‐cell function and anti‐diabetic pharmacotherapy
Prato, S. D., Bianchi, C., & Marchetti, P. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.770 · Cited by 79
Harding, J. L., Weber, M. B., & Shaw, J. E. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch3 · Cited by 80
Efficacy of telemedicine on glycaemic control in patients with type 2 diabetes: A meta-analysis
De Groot, J., Wu, D., Flynn, D., Robertson, D., Grant, G., & Sun, J. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i2.170 · Cited by 77
Wang, C. C. L., & Reusch, J. E. B. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.036 · Cited by 78
Davies, M. J., Chatterjee, S., & Khunti, K. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s82008 · Cited by 78
Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management
Khunti, K., Zaccardi, F., Amod, A., Aroda, V. R., Montoya, P. A., Colagiuri, S., Mohan, V., & Chan, J. C. N. (2024) · Diabetologia · doi:10.1007/s00125-024-06254-w · Cited by 78
Amarenco, P., Goldstein, L. B., Messig, M., O’Neill, B. J., Callahan, A., Sillesen, H. H., Hennerici, M. G., Zivin, J. A., & Welch, K. M. A. (2009) · Stroke · doi:10.1161/strokeaha.108.546135 · Cited by 77
Hayashino, Y., Fukuhara, S., Akiba, T., Akizawa, T., Asano, Y., Saitō, A., Bragg‐Gresham, J. L., Ramirez, S., Port, F. K., & Kurokawa, K. (2007) · Diabetologia · doi:10.1007/s00125-007-0650-z · Cited by 77
Shared care with task delegation to nurses for type 2 diabetes: prospective observational study.
Ubink-Veltmaat, L. J., Bilo, H. J. G., Groenier, K. H., Rischen, R., & Jong, B. M. (2005) · PubMed · Cited by 77
Houlden, R. L. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.001 · Cited by 77
Ferrannini, G., De Bacquer, D., De Backer, G., Kotseva, K., Mellbin, L., Wood, D., Rydén, L., collaborators, E. V., Gale, C. P., Beleslin, B., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2165 · Cited by 75
Holzmann, M. J., Rathsman, B., Eliasson, B., Kuhl, J., Svensson, A., Nyström, T., & Sartipy, U. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.052 · Cited by 76
Siwasaranond, N., Nimitphong, H., Manodpitipong, A., Saetung, S., Chirakalwasan, N., Thakkinstian, A., & Reutrakul, S. (2018) · Journal of Diabetes Research · doi:10.1155/2018/9269170 · Cited by 75
Prevention and Management Strategies for Diabetic Neuropathy
Smith, S., Normahani, P., Lane, T. R. A., Hohenschurz‐Schmidt, D., Oliver, N. S., & Davies, A. H. (2022) · Life · doi:10.3390/life12081185 · Cited by 80
Metadata
- Authors
- Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O.
- Affiliations
- Steno Diabetes Center Copenhagen (DK)
- Herlev Hospital (DK)
- Roskilde Sygehus (DK)
- Aarhus University (DK)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-01-30
- Volume
- 348
- Issue
- 5
- Pages
- 383-393
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139634859
- Cited by
- 4,378
- References
- 26
- Citations by year
- 2026: 47 · 2025: 71 · 2024: 108 · 2023: 110 · 2022: 102 · 2021: 137 · 2020: 142 · 2019: 133 · 2018: 171 · 2017: 143 · 2016: 158 · 2015: 169 · 2014: 198 · 2013: 184 · 2012: 235
- FWCI
- 178.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cardiovascular disease, multifactorial intervention, microalbuminuria, tight glycemic control, hyperglycemia, hypertension, dyslipidemia, aspirin, myocardial infarction, stroke, kidney disease, retinopathy, autonomic neuropathy
- MeSH terms
- Amputation, Surgical, Angiotensin II, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Combined Modality Therapy, Diabetes Mellitus, Diabetes Mellitus, Type 2, Female, Humans, Hyperlipidemias, Hypertension, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Obesity, Risk Factors, Vitamins, Exercise, Smoking Cessation, Diet, Fat-Restricted, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
